Fusion Pharmaceuticals Inc (FUSN)
$2.59
Insights on Fusion Pharmaceuticals Inc
Increasing Revenue
Revenue is up for the last 2 quarters, 28.0K → 34.0K (in $), with an average increase of 17.7% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -24.29M → -25.17M (in $), with an average decrease of 3.6% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 283.9% return, outperforming this stock by 301.1%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 452.1% return, outperforming this stock by 531.7%
Performance
- $2.52$2.62$2.59
2.7%
Downside
Day's Volatility :3.63%
Upside
0.96%
- $1.98$5.63$2.59
23.55%
Downside
52 Weeks Volatility :64.83%
Upside
54.0%
Returns
| Period | Fusion Pharmaceuticals Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -42.35% | 0.0% | 0.0% |
6 Months | -35.32% | 3.0% | -0.5% |
1 Year | -17.2% | 7.2% | 0.4% |
3 Years | -79.61% | 27.5% | 19.1% |
Highlights
Market Capitalization | 179.4M |
Book Value | $2.94 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -1.93 |
Wall Street Target Price | 13.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -27116.85% |
Return On Assets TTM | -25.13% |
Return On Equity TTM | -48.82% |
Revenue TTM | 368.0K |
Revenue Per Share TTM | 0.01 |
Quarterly Revenue Growth YOY | -94.0% |
Gross Profit TTM | -57.4M |
EBITDA | -98.7M |
Diluted Eps TTM | -1.93 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.71 |
EPS Estimate Next Year | -1.65 |
EPS Estimate Current Quarter | -0.39 |
EPS Estimate Next Quarter | -0.39 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 401.93%
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Fusion Pharmaceuticals Inc | -5.11% | -35.32% | -17.2% | -79.61% | -84.71% |
 Moderna, Inc. | -6.8% | -31.93% | -17.68% | 49.48% | 456.61% |
 Regeneron Pharmaceuticals, Inc. | -1.51% | 9.46% | 21.47% | 49.65% | 113.08% |
 Novo Nordisk A/s | 2.45% | 158.58% | 283.85% | 452.05% | 699.12% |
 Seagen, Inc. | 7.08% | 3.54% | 46.23% | 15.75% | 166.19% |
 Vertex Pharmaceuticals Incorporated | 0.45% | 16.4% | 25.65% | 33.45% | 95.64% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Fusion Pharmaceuticals Inc | NA | NA | NA | -1.71 | -0.49 | -0.25 | 0.0 | 2.94 |
Moderna, Inc. | 39.67 | 39.67 | 0.0 | -3.66 | 0.07 | 0.01 | 0.0 | 44.49 |
Regeneron Pharmaceuticals, Inc. | 21.65 | 21.65 | 9.01 | 41.82 | 0.19 | 0.1 | 0.0 | 225.94 |
Novo Nordisk A/s | 44.47 | 44.47 | 2.03 | 3.32 | 0.82 | 0.22 | 0.01 | 2.52 |
Seagen, Inc. | NA | NA | 18.53 | -3.47 | -0.26 | -0.13 | 0.0 | 13.96 |
Vertex Pharmaceuticals Incorporated | 26.73 | 26.73 | 0.41 | 14.71 | 0.25 | 0.16 | 0.0 | 60.01 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Fusion Pharmaceuticals Inc | Buy | $179.4M | -84.71% | NA | 0.0% |
Moderna, Inc. | Buy | $39.4B | 456.61% | 39.67 | 11.33% |
Regeneron Pharmaceuticals, Inc. | Buy | $90.3B | 113.08% | 21.65 | 33.93% |
Novo Nordisk A/s | Buy | $423.8B | 699.12% | 44.47 | 33.4% |
Seagen, Inc. | Hold | $38.9B | 166.19% | NA | -33.55% |
Vertex Pharmaceuticals Incorporated | Buy | $90.9B | 95.64% | 26.73 | 35.4% |
Institutional Holdings
Federated Hermes Inc
15.41%Avidity Partners Management LP
8.26%FMR Inc
6.79%Johnson & Johnson
5.32%Orbimed Advisors, LLC
4.53%Canada Pension Plan Investment Board
4.52%
Corporate Announcements
Fusion Pharmaceuticals Inc Earnings
Fusion Pharmaceuticals Inc’s price-to-earnings ratio stands at None
Read More
Company Information
fusion pharmaceuticals (www.fusionpharma.com) is a new pharmaceutical company located in hamilton, ontario, canada, that is focused on becoming the leader in the targeted alpha therapy field. fusion will exploit its unique expertise in linking medical isotopes to targeting molecules to create highly effective therapeutics. in addition to its lead program, fpx-01, fusion is building a pipeline of products through a protein discovery platform, that allows for the rapid screening of new targeting molecules to promote biomarker localization of alpha emitting medical isotopes. fusion’s technology development team also has proprietary methods for introducing alpha emitters into targeting molecules.
Organization | Fusion Pharmaceuticals Inc |
Employees | 101 |
CEO | Dr. John F. Valliant Ph.D. |
Industry | Health Technology |
